LOGIN  |  REGISTER
Chimerix
Cue Biopharma

Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2023

February 22, 2024 | Last Trade: US$22.81 0.11 -0.48

BANNOCKBURN, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights

  • Net revenue of $1,124.4 million, up 9.5% compared to $1,027.2 million in the fourth quarter of 2022
  • Gross profit of $247.1 million, or 22.0% of revenue, up 6.9% compared to $231.1 million, or 22.5% of revenue, in the fourth quarter of 2022
  • Net income of $57.2 million, or $0.32 earnings per share, inclusive of the impact from non-operating income, compared to net income of $47.5 million, or $0.26 earnings per share in the fourth quarter of 2022
  • Adjusted EBITDA of $111.6 million, up 18.4% compared to $94.3 million in the fourth quarter of 2022
  • Cash flow from operations of $51.0 million, and cash balances of $343.8 million at the end of the fourth quarter
  • The Company announced that it fulfilled $250 million in share repurchases and the Board of Directors authorized an additional $250 million share repurchase authorization

Full Year 2023 Financial Highlights

  • Net revenue of $4,302.3 million, up 9.1% compared to $3,944.7 million in full year 2022
  • Gross profit of $981.2 million, or 22.8% of revenue, up 13.2% compared to $866.9 million, or 22.0% of revenue, in full year 2022
  • Net income of $267.1 million, or $1.48 diluted earnings per share, compared to net income of $150.6 million, or $0.83 earnings per share, in full year 2022
  • Adjusted EBITDA of $425.2 million, up 24.0% compared to $342.9 million in full year 2022
  • Cash flow from operations of $371.3 million, up 38.8% compared to $267.5 million in full year 2022

John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team delivered strong financial results in the fourth quarter and full year of 2023 and continued to execute on our commitment to clinical excellence by providing extraordinary patient care through our resilient national platform. The patient is at the center of everything we do, and I am excited to build on this momentum in 2024 to further our mission to provide innovative services that improve outcomes, reduce costs, and deliver hope for patients and families.”

Full Year 2024 Financial Guidance

For the full year 2024, Option Care Health expects to deliver the following financial results:

  • Net revenue of $4.6 billion to $4.8 billion
  • Adjusted EBITDA of $425 million to $450 million
  • Cash flow from operations of at least $300 million

Additionally, the Company anticipates an effective tax rate of 26% - 28% and net interest expense of approximately $55 million to $60 million.

Conference Call

Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members, including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at OptionCareHealth.com.

Investor Contacts

Mike ShapiroBob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial OfficerWestwicke
T: (312) 940-2538T: (413) 213-0500
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

Schedule 1

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)

 

 

 December 31,
  2023  2022
ASSETS   
CURRENT ASSETS:   
Cash and cash equivalents$343,849 $294,186
Accounts receivable, net 377,658  377,542
Inventories 274,004  224,281
Prepaid expenses and other current assets 98,744  98,330
Total current assets 1,094,255  994,339
    
NONCURRENT ASSETS:   
Property and equipment, net 120,630  108,321
Intangible assets, net 20,092  22,371
Referral sources, net 315,304  341,744
Goodwill 1,540,246  1,533,424
Other noncurrent assets 126,508  112,737
Total noncurrent assets 2,122,780  2,118,597
TOTAL ASSETS$3,217,035 $3,112,936
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
CURRENT LIABILITIES:   
Accounts payable$426,513 $378,763
Other current liabilities 191,796  186,588
Total current liabilities 618,309  565,351
    
NONCURRENT LIABILITIES:   
Long-term debt, net of discount, deferred financing costs and current portion 1,056,650  1,058,204
Other noncurrent liabilities 120,404  103,278
Total noncurrent liabilities 1,177,054  1,161,482
Total liabilities 1,795,363  1,726,833
    
STOCKHOLDERS' EQUITY 1,421,672  1,386,103
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,217,035 $3,112,936
 

Schedule 2

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

 

 

 Three Months Ended
December 31,
 Year Ended
December 31,
  2023   2022   2023   2022 
NET REVENUE$1,124,390  $1,027,213  $4,302,324  $3,944,735 
COST OF REVENUE 877,267   796,132   3,321,101   3,077,817 
GROSS PROFIT 247,123   231,081   981,223   866,918 
        
OPERATING COSTS AND EXPENSES:       
Selling, general and administrative expenses 147,783   148,351   607,427   566,122 
Depreciation and amortization expense 14,784   14,538   59,201   60,565 
Total operating expenses 162,567   162,889   666,628   626,687 
OPERATING INCOME 84,556   68,192   314,595   240,231 
        
OTHER INCOME (EXPENSE):       
Interest expense, net (12,432)  (14,798)  (51,248)  (53,806)
Other, net 6,801   11,387   95,395   19,343 
Total other (expense) income (5,631)  (3,411)  44,147   (34,463)
        
INCOME BEFORE INCOME TAXES 78,925   64,781   358,742   205,768 
INCOME TAX EXPENSE 21,748   17,252   91,652   55,212 
NET INCOME$57,177  $47,529  $267,090  $150,556 
        
Earnings per share, basic$0.32  $0.26  $1.49  $0.83 
Earnings per share, diluted$0.32  $0.26  $1.48  $0.83 
        
Weighted average common shares outstanding, basic 176,055   181,925   178,973   181,105 
Weighted average common shares outstanding, diluted 177,743   183,086   180,375   182,075 
  

Schedule 3

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)

 

 

 Year Ended
December 31,
  2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:   
Net income$267,090  $150,556 
Adjustments to reconcile net income to net cash provided by operations:   
Depreciation and amortization expense 62,200   65,434 
Deferred income taxes - net 12,766   49,187 
Other non-cash adjustments 50,684   32,147 
Changes in operating assets and liabilities:   
Accounts receivable, net 224   (36,889)
Inventories (51,000)  (41,010)
Accounts payable 47,703   98,885 
Other (18,372)  (50,763)
Net cash provided by operating activities 371,295   267,547 
    
CASH FLOWS FROM INVESTING ACTIVITIES:   
Acquisition of property and equipment (41,866)  (35,358)
Proceeds from sale of assets 3,743   14,670 
Business acquisitions, net of cash acquired (12,494)  (87,364)
Other investing activities (5,889)   
Net cash used in investing activities (56,506)  (108,052)
    
CASH FLOWS FROM FINANCING ACTIVITIES:   
Proceeds from warrant exercises    20,916 
Purchase of company stock (250,261)   
Other financing activities (14,865)  (5,648)
Net cash (used in) provided by financing activities (265,126)  15,268 
    
NET INCREASE IN CASH AND CASH EQUIVALENTS 49,663   174,763 
Cash and cash equivalents - beginning of the period 294,186   119,423 
CASH AND CASH EQUIVALENTS - END OF PERIOD$343,849  $294,186 
 

Schedule 4

OPTION CARE HEALTH, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)

 

 

 Three Months Ended 
 December 31,
 Year Ended
December 31,
  2023   2022   2023   2022 
Net income$57,177  $47,529  $267,090  $150,556 
Interest expense, net 12,432   14,798   51,248   53,806 
Income tax expense 21,748   17,252   91,652   55,212 
Depreciation and amortization expense 15,777   15,711   62,200   65,434 
EBITDA 107,134   95,290   472,190   325,008 
        
EBITDA adjustments       
Stock-based incentive compensation expense 7,571   4,202   30,479   16,783 
Gain on sale of assets    (10,325)     (10,325)
Restructuring, acquisition, integration and other (1) (3,103)  5,105   (77,486)  11,387 
Adjusted EBITDA$111,602  $94,272  $425,183  $342,853 
 

(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of merger-related expenses

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB